Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 147Cholangiocarcinoma 26Liver Neoplasms 17Stomach Neoplasms 13Biliary Tract Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 8Neoplasms 7Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Liver Diseases 3Esophageal Neoplasms 3Cirrhosis, Familial, with Pulmonary Hypertension 3Carcinoma 3Advanced Biliary Tract Cancer 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms, Glandular and Epithelial 2Melanoma 2Hepatitis B 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms Immunotherapy 2Uterine Cervical Neoplasms 1

Interventions

Gemcitabine 6Cisplatin 6Capecitabine 6Liver Transplantation 4Fluorouracil 4Specimen Handling 3Radiosurgery 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3toripalimab 2dehydroftorafur 2Self Expandable Metallic Stents 2Platinum 2Leucovorin 2Biopsy 23-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 21,2-diaminocyclohexaneplatinum II citrate 2trisacryl gelatin microspheres 1tremelimumab 1trametinib 1tislelizumab 1temoporfin 1sacituzumab govitecan 1ricolinostat 1pembrolizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1durvalumab 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Klatskin Tumor × lenvatinib × Gastrointestinal × Clear all
NCT04211168 2023-03-29

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Peking Union Medical College Hospital

Phase 2 Unknown
44 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡